Y
Ying-Ying Zheng
Researcher at Zhengzhou University
Publications - 42
Citations - 3028
Ying-Ying Zheng is an academic researcher from Zhengzhou University. The author has contributed to research in topics: Percutaneous coronary intervention & Coronary artery disease. The author has an hindex of 9, co-authored 38 publications receiving 2131 citations. Previous affiliations of Ying-Ying Zheng include First Affiliated Hospital of Xinjiang Medical University.
Papers
More filters
Journal ArticleDOI
COVID-19 and the cardiovascular system.
TL;DR: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through ACE2 receptors, leading to coronav virus disease (COVID-19)-related pneumonia, while also causing acute myocardial injury and chronic damage to the cardiovascular system.
Journal ArticleDOI
Atherogenic index of plasma (AIP): a novel predictive indicator for the coronary artery disease in postmenopausal women
TL;DR: The present study indicated that Atherogenic index of plasma might be a strong marker for predicting the risk of CAD in postmenopausal women.
Journal ArticleDOI
Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
Ying-Ying Zheng,Ying-Ying Zheng,Ting-Ting Wu,Yi Yang,Xian-Geng Hou,Ying Gao,You Chen,Yi-Ning Yang,Xiao-Mei Li,Xiang Ma,Yi-Tong Ma,Xiang Xie +11 more
TL;DR: It is suggested that personalized antiplatelet therapy according to MAR can significantly improve the net clinical benefit 180 days after PCI, and theNet clinical adverse events were significantly reduced in the personalized group at 30 Days after PCI compared to the standard group.
Journal ArticleDOI
Reply to: 'Interaction between RAAS inhibitors and ACE2 in the context of COVID-19'.
TL;DR: Although ACE2 has been identified as the functional receptor for SARSCoV-2, the role of ACE2 in the progression of COVID-19 after SARSConavirus 2 infection is still controversial, so the benefits of aliskiren use in patients with COVID19 needs further investigation.
Journal ArticleDOI
Gamma-Glutamyl Transferase-to-Platelet Ratio as a Novel Predictor of Long-Term Adverse Outcomes in Patients after Undergoing Percutaneous Coronary Intervention: A Retrospective Cohort Study.
Ying-Ying Zheng,Ying-Ying Zheng,Ting-Ting Wu,You Chen,Xian-Geng Hou,Yi Yang,Xiang Ma,Yi-Tong Ma,Jin-Ying Zhang,Xiang Xie +9 more
TL;DR: It is indicated that GPR is an independent and novel predictor of adverse long-term outcomes in CAD patients who underwent percutaneous coronary intervention (PCI) and in acute coronary syndrome (ACS) patients.